Firazyr (Icatibant)

Firazyr is indicated for the management of acute episodes of hereditary angioedema (HAE) in patients with type I or type II deficiency.

• Treatment of sudden swelling of the face, lips, tongue, or extremities associated with HAE.
• Relief of abdominal pain and gastrointestinal edema caused by HAE attacks.
• Use in patients who have previously responded to icatibant therapy.
• Administration when other on‑demand therapies are unavailable or contraindicated.
• Option for self‑administration at home under medical supervision.

The safety profile of Firazyr includes both frequently observed and less common adverse events.

Common

• Injection site pain, redness, or swelling.
• Transient headache.
• Nausea or mild gastrointestinal discomfort.
• Flushing of the skin.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing.
• Hypotension or sudden drop in blood pressure.
• Angioedema at a site other than the HAE episode.
• Persistent or worsening abdominal pain.

Before using Firazyr, healthcare providers should consider several precautionary measures to ensure safe administration.

• Assess patient history for hypersensitivity to icatibant or any formulation components.
• Use caution in patients with cardiovascular disease or low blood pressure.
• Monitor for signs of anaphylaxis after injection, especially during the first dose.
• Do not administer if the patient is currently experiencing a severe allergic reaction.
• Evaluate pregnancy status; safety data are limited, and the drug is classified as pregnancy category unknown.
• Adjust dosing only under specialist guidance; off‑label use is not recommended.

Firazyr may interact with other medicines, and certain combinations should be avoided or used with clinical monitoring.

Avoid

• Concurrent use of ACE inhibitors or angiotensin receptor blockers that can increase bradykinin levels.
• Simultaneous administration of other bradykinin B2 receptor antagonists.

Use with caution

• Concomitant use of diuretics that may affect blood pressure.
• Co‑administration with other biologic agents for HAE, such as C1‑esterase inhibitor concentrates.
• Use alongside medications that cause hypotension, requiring blood pressure monitoring.